Anavex Life Sciences Reports Q3 2026 Financial Results and Advances Clinical Programs; Notes Former CEO Termination

Anavex Life Sciences Corp. (Nasdaq: AVXL) reported its third fiscal quarter 2026 financial results, including a net income of $7.8 million, or $0.08 per share. The company also provided a business update, highlighting continued regulatory momentum across its pipeline for Alzheimer's disease, Rett syndrome, and Fragile X syndrome. The financial results noted a reversal of stock-based compensation expense primarily related to the termination of employees, including the former Chief Executive Officer.